MOLECULAR BASIS OF LANGUAGE DEVELOPMENT AND ASSOCIATED DISORDERS

Last updated: April 1, 2025
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France
Overall Status: Active - Recruiting

Phase

N/A

Condition

Speech Disorders

Communication Disorders

Treatment

blood draw

Clinical Study ID

NCT06660108
C23-79
IDRCB
  • Ages > 5
  • All Genders

Study Summary

Developmental Language Disorder (DLD) refers to children who present with language difficulties that are not due to a known biomedical condition or associated with autism spectrum disorder (ASD) or intellectual disability. The prevalence of DLD is ~7%-8% or 2% if severe forms are considered.

However, the clinical heterogeneity of language disorders, the presence of co-morbidities and the inconsistent terminology used for many years have hindered research and clinical practice. Distinguishing sub-groups of children with language problems is crucial when tackling the underlying genetic causes of this disease. Recently, several studies using high-throughput sequencing have better define the genetic basis of CAS but such studies focusing on DLD are limited. The investigation of more homogeneous cohorts of individuals that clearly distinguish DLD cases, from ID and not including children with CAS should improve our understanding of the genetic basis of this disorder.

In this study, we aim to built and investigate a well-characterized cohort of DLD patients using pangenomic approaches to better define the molecular basis of this disorder. All individuals will be analyzed using chromosomal microarray analysis and whole genome sequencing. Multiple observations and preliminary results suggest strong links with the genetic basis of other neurodevelopmental disorders.

The goal is to identify CNV or SNV as causative allele or risk factor and already known to be involved in other neurodevelopmental disorders as well as potential new variants.

Eligibility Criteria

Inclusion

Patients

Inclusion Criteria:

  • Eligible families included at least one child over five years old with a formaldiagnosis of severe and isolated DLD according to Phase 2 CATALISE criteria .Patients have undergone age-appropriate speech, language and reading evaluations bya speech-language physician and cognitive evaluations by a neuropsychologist, aswell as evaluation by a pediatric neurologist to identify co-occurring developmentaldisorders (ADHD, ASD...) and a medical geneticist for known genetic disorders andgenetic testing recommendations. All children included received appropriate speechtherapy for at least one year, with a progress report indicating the persistence oflanguage difficulties.

Exclusion

Exclusion Criteria:

  • Cognitive impairment with non-verbal intellectual quotient (IQ) below 2 SD assessedwith the Wechsler Preschool and Primary Scale of Intelligence (WPPSI), or theWechsler Intelligence Scale for Children (WISC-IV or V) according to theage-appropriateness, ASD, moderate to severe hearing loss, orofacial structuralabnormalities, known neurological or genetic disorders at the initial assessment.None of the patients met the diagnostic criteria for CAS according to the ASHA (American Speech-Language-Hearing Association, 2007. Childhood apraxia of speechwww.asha.org/policy).

Study Design

Total Participants: 50
Treatment Group(s): 1
Primary Treatment: blood draw
Phase:
Study Start date:
March 25, 2025
Estimated Completion Date:
March 25, 2028

Connect with a study center

  • Hopital Sud Francilien

    Corbeil Essonnes, 91100
    France

    Active - Recruiting

  • Raymond Poincaré- Garches

    Garches, 92380
    France

    Active - Recruiting

  • Hopital Necker

    Paris, 75015
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.